乳腺癌组织中BCAR1 p130Cas蛋白的表达及其临床意义  

The Expression of BCAR1/p130Cas Protein in Breast Cancer and Its Significance

作　　者：路洪超[1] 耿翠芝[2] 宋连柱[1] 王荣茂[1] 陈萌[1] 杨瑞玲[2] 周军[2] 

机构地区：[1]河北省复员军人医院外二科,河北省邢台市054000 [2]河北医科大学第四医院外一科

出　　处：《中国肿瘤临床》2009年第1期29-32,共4页Chinese Journal of Clinical Oncology

基　　金：河北省高等院校强势特色学科基金资助(编号:冀教高[2005]52号)

摘　　要：目的：探讨BCAR1／p130Cas蛋白在乳腺癌组织中的表达及其与乳腺癌内分泌治疗耐药及预后的关系。方法：选择ER阳性且经过规范化内分泌治疗和随访5年资料完整的乳腺癌患者67例，应用免疫组化方法检测其BCAR1／p130Cas蛋白表达情况，回顾性分析BCAR1／p130Cas蛋白表达与乳腺癌的临床生物学特征及预后的关系。结果：在发生局部复发或远位转移的29例患者中，25例呈现BCAR1／p130Cas蛋白高表达，占86．2％，无复发转移的38例中，BCAR1／p130Cas蛋白高表达仅为21．1％，两组差异显著（χ^2=27．935，P=0．000）；乳腺癌组织中BCAR1／p130Cas蛋白表达与高组织学分级（r=0．270，P=0．027）、C—erbB-2蛋白高表达（r=0．492，P=0．000）以及绝经状况（χ^2=13．77．P=0．003）呈现正相关；与肿瘤大小（P=0．548）、病理类型（P=0．177）、淋巴结状况（P=0．720）、TNM分期（P=0．524）无统计学差异（P〉0．05）。结论：BCAR1／p130Cas蛋白的表达水平与肿瘤的侵袭性显著相关，BCAR1／p130Cas蛋白的表达水平越高肿瘤的恶性程度越高，所以BCAR1／p130Cas蛋白高表达患者的复发、转移风险增加；BCAR1／p130CaS蛋白高表达与三苯氧胺治疗耐药密切相关；芳香化酶抑制剂是绝经后ER阳性乳腺癌患者内分泌治疗的最佳选择。BCAR1／p130Cas蛋白的表达水平和腋淋巴结转移状况、肿瘤大小、病理类型、TNM分期无关。因此认为，BCAR1／p130Cas蛋白可以作为独立判定乳腺癌预后的一个重要参数，为监测乳腺癌的转移提供了一个有价值的指标，有助于乳腺癌复发转移的诊断及治疗。Objective： To detect the expression of BCAR1/p130Cas protein in primary breast cancer and its antiestrogen resistance during endocrine therapy, and to investigate the relationship between expression of the BCAR1 gene and the prognosis of breast cancer. Methods： A total of 67 ER-positive primary breast cancer patients were randomly recruited between 2000 and 2001. These patients received standardized therapy including endocrine therapy and were followed up for 5 years. We used immunohistochemistry to detect the expression of BCAR1/p130Cas protein in the breast cancer samples. We also analyzed the association between BCAR1/p130Cas protein expression and clinicopathologic features including tumor size, pathological type, differentiation degree, menstruation status, lymph node metastasis, TNM staging, and efficacy of tamox- ifen for endocrine therapy. Results： Of the 67 ER-positive breast cancer cases, 29 died of disease recurrence or metastasis. The other 38 patients had no recurrence or metastasis. Of the 29 patients who died of recurrence or metastasis, 25 cases were BCAR1/p130Cas protein positive, accounting for 86.2%. Of the 38 patients without disease recurrence or metastasis, there were only 8 patients with BCAR1/p130Cas protein expression, accounting for 21.1%. A positive correlation was found between BCAR1/p130Cas protein level and relapse-free survival （χ^ 2=27.935; P=0.000）. A positive correlation was found between the expression of BCAR1/p130Cas protein and differentiation degree （r=0.270, P=-0.027）. A positive correlation was also found between the expression of BCAR1/p130Cas protein and protein expression of C-erbB-2 （r=0.492, P=0.000）in ER-positive breast cancer tissues. BCAR1/p130Cas protein expression was correlated with menstruation status （χ^2=13.77, P=0.003）. No correlation was found between the expression of BCAR1/p130Cas protein and tumor size （P=0.548）, pathological type （P=0.177）, lymph node metastasis （P=0.720） or TNM stage （P=0.524）. Conclusion： Brea

关 键 词：免疫组化 BCAR1/p130cas蛋白 抗雌激素药物耐药 预后 乳腺肿瘤 

分 类 号：R737.9[医药卫生—肿瘤] R563.1[医药卫生—临床医学]